Vertex Pharmaceuticals News Archives

More than 80 percent of hepatitis C patients in each arm of the Phase 2 Study C208 achieved a sustained viral response with a telaprevir-based regimen according to results of an intent-to-treat analysis announced today by Vertex Pharmaceuticals Incorporated .

SUMMARY: The 60th Annual Meeting of the American Association for the Study of Liver Diseases -- better known as " The Liver Meeting " -- gets underway Friday, October 30, and will run through November 1 at the Hynes Convention Center in Boston.

Vertex Pharmaceuticals Incorporated announced today that treatment with telaprevir-based regimens in Study 107 resulted in high sustained viral response rates in treatment-failure patients infected with hepatitis C virus .

Vertex Pharmaceuticals Inc. said Wednesday its hepatitis C treatment telaprevir created an immune system response to the virus in patients who had not been helped by other drugs.

Vertex Pharmaceuticals Inc. reported a larger third-quarter loss on Monday, as revenue fell and the company spent more money to support the launch of its hepatitis C drug candidate.

Vertex holds first companywide 'day of service' Vertex Pharmaceuticals Inc. encouraged 800 employees to take part in Vertex's first companywide Day of Service, which was held Sept.

Virginia Carnahan, vice president of new product planning and strategy at Vertex Pharmaceuticals, reflects on the industry's changing environment and how to adapt to remain competitive.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

The hepatitis C drug telaprevir from Vertex Pharmaceuticals is working its way through phase III clinical trials and is widely expected to be the first new drug in years approved for the treatment of the chronic liver disease.

Talecris Biotherapeutics raised $950 million in the biggest biopharma IPO in three years and the second largest U.S. IPO this year even as the stock market fell as declines in factory orders and increases in job cuts heightened concerns about the economy's recovery.

With shouts of joy from investors and the Foolish analysts who cover them, the IPO market seems wide open once again for companies with "pharmaceutical" or "biotherapeutics" in their names.

Milestone payments have Vertex Pharmaceuticals Inc. seeing green with an expected cash infusion of $155 million from two separate transactions.

Vertex Pharmaceuticals Incorporated today announced that it will receive $155 million in cash from two financial transactions.